Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 20/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 19/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 19/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823563 | 1.00 | HDAC4 (0.65) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823655 | 1.00 | HDAC4 (0.65) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823555 | 1.00 | HDAC4 (0.65) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823560 | 0.90 | HDAC3 (0.54) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823591 | 0.87 | HDAC3 (0.61) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823581 | 0.87 | HDAC3 (0.59) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823597 | 0.86 | HDAC3 (0.57) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823548 | 0.84 | ALOX5 (0.59) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823701 | 0.83 | HDAC1 (0.60) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL823559 | 0.83 | HDAC1 (0.54) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2318005-B1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2014137741-A1 | HDAC INHIBITORS FOR TREATING TRAUMATIC BRAIN INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8455688-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455688-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8329719-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | HDAC4 191/4885HDAC1 417/4885HDAC7 1115/4885 |
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | HDAC5, HDAC1, HDAC4 | HDAC4 3/4885HDAC1 2/4885HDAC7 7/4885 |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | HDAC1, PPP3CA, PPM1A | HDAC4 19/4885HDAC1 1/4885HDAC7 26/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | HDAC4 3/4885HDAC1 6/4885HDAC7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.